- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
- Ixekizumab and secukinumab for treating active ankylosing spondylitis
Withdrawn
Ixekizumab and secukinumab for treating active ankylosing spondylitis
Condition
Musculoskeletal
Blood and Immune System
31 August 2022
Published on 03 Aug 2021
Last Updated on 31 Aug 2022
Ixekizumab and secukinumab for treating active ankylosing spondylitis Guidance is outdated and has been withdrawn on 31 August 2022. The Plain English Summary (PES) has been updated on 31 August 2022.